"Advances in gene-based vaccine platforms to address the COVID-19 pandemic". Advanced Drug Delivery Reviews (Elsevier) 170: 113–141. 2021-03-01. doi:10.1016/j.addr.2021.01.003. ISSN0169-409X. PMC7789827. "Viral vector vaccines confer high gene transduction capabilities due to the natural ability of viruses to infect host cells. These vaccines do not require adjuvants due to the presence of viral components that stimulate the innate immune system.".
"Advances in gene-based vaccine platforms to address the COVID-19 pandemic". Advanced Drug Delivery Reviews (Elsevier) 170: 113–141. 2021-03-01. doi:10.1016/j.addr.2021.01.003. ISSN0169-409X. PMC7789827. "Viral vector vaccines confer high gene transduction capabilities due to the natural ability of viruses to infect host cells. These vaccines do not require adjuvants due to the presence of viral components that stimulate the innate immune system.".
"Advances in gene-based vaccine platforms to address the COVID-19 pandemic". Advanced Drug Delivery Reviews (Elsevier) 170: 113–141. 2021-03-01. doi:10.1016/j.addr.2021.01.003. ISSN0169-409X. PMC7789827. "Viral vector vaccines confer high gene transduction capabilities due to the natural ability of viruses to infect host cells. These vaccines do not require adjuvants due to the presence of viral components that stimulate the innate immune system.".
